+关注
Charis4455
暂无个人介绍
IP属地：未知
8
关注
1
粉丝
0
主题
0
勋章
主贴
热门
Charis4455
2021-12-15
:(
Upstart Shares Have Plunged, But Stay Away for Now
Charis4455
2021-12-01
Huatz
抱歉，原内容已删除
Charis4455
2021-11-13
Cool
抱歉，原内容已删除
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3582016082149562","uuid":"3582016082149562","gmtCreate":1618922380873,"gmtModify":1623984995436,"name":"Charis4455","pinyin":"charis4455","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/170154e3e4358555276582209b5e7550","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":8,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.16","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.23","exceedPercentage":"60.55%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":607649897,"gmtCreate":1639536362062,"gmtModify":1639536362062,"author":{"id":"3582016082149562","authorId":"3582016082149562","name":"Charis4455","avatar":"https://static.tigerbbs.com/170154e3e4358555276582209b5e7550","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582016082149562","authorIdStr":"3582016082149562"},"themes":[],"htmlText":":(","listText":":(","text":":(","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607649897","repostId":"1180160205","repostType":4,"repost":{"id":"1180160205","kind":"news","pubTimestamp":1639534172,"share":"https://www.laohu8.com/m/news/1180160205?lang=&edition=full","pubTime":"2021-12-15 10:09","market":"us","language":"en","title":"Upstart Shares Have Plunged, But Stay Away for Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1180160205","media":"InvestorPlace","summary":"Even after crashing, UPST stock remains risky","content":"<p><b>Upstart</b> (NASDAQ:<b><u>UPST</u></b>) has been one of this year’s top performers. Shares of UPST stock are up over 250% year-to-date (YTD), from around $40 at the start of 2021 to $145 as of the close of Dec. 14.</p>\n<p>You probably wouldn’t realize that if you’ve just tuned into the Upstart story, however. While UPST is up huge on the year, the gains have shrunk dramatically from where they were back in October. At that point, the stock had briefly hit $400 as speculative fervor peaked.</p>\n<p>The top soon came following an embarrassing interview on<i>CNBC</i>. The business channel had on stock trader Mark Minervini to discuss UPST stock and Minervini talked up the company’s strong technicals and momentum. However, when the <i>CNBC</i> host asked Minervini to explain Upstart’s business model, he froze up. Seemingly unable to answer, Minervini blamed audio issues and the interview abruptly ended.</p>\n<p>That moment went viral and the UPST stock price soon started to crash. It seems a lot of people, like Minervini, appreciated Upstart primarily because of its strong price performance rather than the company’s actual business. With the momentum in the stock long gone, however, is it time to buy in during this correction?</p>\n<p><b>UPST Stock: Rapid But Slowing Growth</b></p>\n<p>At first glance, Upstart’s third-quarter earnings report didn’t look too bad. The company beat estimates on both the top and bottom line. In particular, the earnings figure was substantially ahead of expectations. Based on that, you might have thought Upstart would rally on the results, or at least hold its ground. Instead, UPST stock immediately plunged 20% upon the Q3 release.</p>\n<p>What went wrong? For one thing, investors had their expectations in the stratosphere. Analysts may have had more conservative numbers, but quick money traders were expecting massive growth in Q3 after Q2’s blowout earnings. Instead, Q3 was only moderately ahead of expectations.</p>\n<p>Specifically, Upstart’s growth rate showed the issues. For the quarter, revenue growth slowed to 18% sequentially versus 60% in Q2. That’s a massive decline. And that came even as some analysts have become concerned that Upstart may be lowering loan quality standards to attract more business. Adding to that point, while the company grew revenues sequentially, the contribution margin actually declined slightly in Q3 versus Q2.</p>\n<p>Long story short, Upstart’s incredible growth phase appears to be drawing to a close. Meanwhile, shares are trading at 100 times this year’s earnings and a projected 77 times forward earnings, according to<i>Seeking Alpha</i>. That’s far too high for a company with rapidly slowing revenue and earnings growth. On top of that, add the fact that it faces substantial cyclical concerns if and when the economy turns downward once again.</p>\n<p>UPST stock completed its initial public offering (IPO) at $20 per share just a year ago. It’s no surprise that the stock is having trouble supporting a price 10 times that high just a year later. Momentum traders got way over their skis on this one.</p>\n<p><b>Analysts Also Worry About Valuation</b></p>\n<p>I’m hardly the only person that’s concerned about Upstart’s valuation, too. For example, Morgan Stanley initiated coverage of Upstart shares last week with a neutral rating.</p>\n<p>Morgan Stanley’s James Faucette did credit the company for its rapid growth. However, Faucette also warned that it has benefitted from unusually favorable credit conditions among other tailwinds. The analyst is monitoring Upstart for incremental changes to the growth story.</p>\n<p>In the meantime, it’s not exactly encouraging that Faucette assigned UPST stock a neutral rating on shares with the stock already back under $200. Just because this name hit $400 before doesn’t necessarily mean it’s a bargain below $200 per share.</p>\n<p><b>The Verdict on Upstart</b></p>\n<p>The last time I covered Upstart, I took an unequivocally negative view, warning that it was “overvalued and set to crash.”Indeed, the stock has plunged from $300 to below $160 since that article’s publication. That wasn’t too complicated of a call — there was absolutely no way to justify a valuation anywhere near that level.</p>\n<p>However, the investment case now is a little more nuanced with the stock down a quick 50%. At this point, shares are oversold — rather than overbought — on a short-term basis. To some extent, UPST stock has gotten hit with tax loss and momentum-based selling as people that bought at $300 and above sell out of shares to move their capital elsewhere.</p>\n<p>So, would it be surprising if UPST stock bounces once the calendar flips into 2022? Not at all. Over the longer-term, though, Upstart remains seriously overvalued compared to its medium-term business prospects. The company will need to expand into more lending verticals — without letting credit quality slide — if it’s going to support a triple-digit price going forward.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Upstart Shares Have Plunged, But Stay Away for Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUpstart Shares Have Plunged, But Stay Away for Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-15 10:09 GMT+8 <a href=https://investorplace.com/2021/12/upst-stock-has-plunged-but-stay-away-from-shares-for-now/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Upstart (NASDAQ:UPST) has been one of this year’s top performers. Shares of UPST stock are up over 250% year-to-date (YTD), from around $40 at the start of 2021 to $145 as of the close of Dec. 14.\nYou...</p>\n\n<a href=\"https://investorplace.com/2021/12/upst-stock-has-plunged-but-stay-away-from-shares-for-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UPST":"Upstart Holdings, Inc."},"source_url":"https://investorplace.com/2021/12/upst-stock-has-plunged-but-stay-away-from-shares-for-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180160205","content_text":"Upstart (NASDAQ:UPST) has been one of this year’s top performers. Shares of UPST stock are up over 250% year-to-date (YTD), from around $40 at the start of 2021 to $145 as of the close of Dec. 14.\nYou probably wouldn’t realize that if you’ve just tuned into the Upstart story, however. While UPST is up huge on the year, the gains have shrunk dramatically from where they were back in October. At that point, the stock had briefly hit $400 as speculative fervor peaked.\nThe top soon came following an embarrassing interview onCNBC. The business channel had on stock trader Mark Minervini to discuss UPST stock and Minervini talked up the company’s strong technicals and momentum. However, when the CNBC host asked Minervini to explain Upstart’s business model, he froze up. Seemingly unable to answer, Minervini blamed audio issues and the interview abruptly ended.\nThat moment went viral and the UPST stock price soon started to crash. It seems a lot of people, like Minervini, appreciated Upstart primarily because of its strong price performance rather than the company’s actual business. With the momentum in the stock long gone, however, is it time to buy in during this correction?\nUPST Stock: Rapid But Slowing Growth\nAt first glance, Upstart’s third-quarter earnings report didn’t look too bad. The company beat estimates on both the top and bottom line. In particular, the earnings figure was substantially ahead of expectations. Based on that, you might have thought Upstart would rally on the results, or at least hold its ground. Instead, UPST stock immediately plunged 20% upon the Q3 release.\nWhat went wrong? For one thing, investors had their expectations in the stratosphere. Analysts may have had more conservative numbers, but quick money traders were expecting massive growth in Q3 after Q2’s blowout earnings. Instead, Q3 was only moderately ahead of expectations.\nSpecifically, Upstart’s growth rate showed the issues. For the quarter, revenue growth slowed to 18% sequentially versus 60% in Q2. That’s a massive decline. And that came even as some analysts have become concerned that Upstart may be lowering loan quality standards to attract more business. Adding to that point, while the company grew revenues sequentially, the contribution margin actually declined slightly in Q3 versus Q2.\nLong story short, Upstart’s incredible growth phase appears to be drawing to a close. Meanwhile, shares are trading at 100 times this year’s earnings and a projected 77 times forward earnings, according toSeeking Alpha. That’s far too high for a company with rapidly slowing revenue and earnings growth. On top of that, add the fact that it faces substantial cyclical concerns if and when the economy turns downward once again.\nUPST stock completed its initial public offering (IPO) at $20 per share just a year ago. It’s no surprise that the stock is having trouble supporting a price 10 times that high just a year later. Momentum traders got way over their skis on this one.\nAnalysts Also Worry About Valuation\nI’m hardly the only person that’s concerned about Upstart’s valuation, too. For example, Morgan Stanley initiated coverage of Upstart shares last week with a neutral rating.\nMorgan Stanley’s James Faucette did credit the company for its rapid growth. However, Faucette also warned that it has benefitted from unusually favorable credit conditions among other tailwinds. The analyst is monitoring Upstart for incremental changes to the growth story.\nIn the meantime, it’s not exactly encouraging that Faucette assigned UPST stock a neutral rating on shares with the stock already back under $200. Just because this name hit $400 before doesn’t necessarily mean it’s a bargain below $200 per share.\nThe Verdict on Upstart\nThe last time I covered Upstart, I took an unequivocally negative view, warning that it was “overvalued and set to crash.”Indeed, the stock has plunged from $300 to below $160 since that article’s publication. That wasn’t too complicated of a call — there was absolutely no way to justify a valuation anywhere near that level.\nHowever, the investment case now is a little more nuanced with the stock down a quick 50%. At this point, shares are oversold — rather than overbought — on a short-term basis. To some extent, UPST stock has gotten hit with tax loss and momentum-based selling as people that bought at $300 and above sell out of shares to move their capital elsewhere.\nSo, would it be surprising if UPST stock bounces once the calendar flips into 2022? Not at all. Over the longer-term, though, Upstart remains seriously overvalued compared to its medium-term business prospects. The company will need to expand into more lending verticals — without letting credit quality slide — if it’s going to support a triple-digit price going forward.","news_type":1},"isVote":1,"tweetType":1,"viewCount":688,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603919337,"gmtCreate":1638350710918,"gmtModify":1638350710990,"author":{"id":"3582016082149562","authorId":"3582016082149562","name":"Charis4455","avatar":"https://static.tigerbbs.com/170154e3e4358555276582209b5e7550","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582016082149562","authorIdStr":"3582016082149562"},"themes":[],"htmlText":"Huatz ","listText":"Huatz ","text":"Huatz","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/603919337","repostId":"1116877933","repostType":2,"isVote":1,"tweetType":1,"viewCount":575,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879574401,"gmtCreate":1636758992535,"gmtModify":1636758992535,"author":{"id":"3582016082149562","authorId":"3582016082149562","name":"Charis4455","avatar":"https://static.tigerbbs.com/170154e3e4358555276582209b5e7550","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582016082149562","authorIdStr":"3582016082149562"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879574401","repostId":"1163118124","repostType":4,"isVote":1,"tweetType":1,"viewCount":795,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":603919337,"gmtCreate":1638350710918,"gmtModify":1638350710990,"author":{"id":"3582016082149562","authorId":"3582016082149562","name":"Charis4455","avatar":"https://static.tigerbbs.com/170154e3e4358555276582209b5e7550","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582016082149562","authorIdStr":"3582016082149562"},"themes":[],"htmlText":"Huatz ","listText":"Huatz ","text":"Huatz","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/603919337","repostId":"1116877933","repostType":2,"repost":{"id":"1116877933","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638350081,"share":"https://www.laohu8.com/m/news/1116877933?lang=&edition=full","pubTime":"2021-12-01 17:14","market":"us","language":"en","title":"Merck shares jumped 5.3% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1116877933","media":"Tiger Newspress","summary":"Merck shares jumped 5.3% in premarket trading as FDA advisers recommended its COVID-19 pill in close","content":"<p>Merck shares jumped 5.3% in premarket trading as FDA advisers recommended its COVID-19 pill in close vote.</p>\n<p><img src=\"https://static.tigerbbs.com/52b0f147fff1ac74d32cd5d5643fe2b3\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p>\n<p>The Food and Drug Administration advisory committee said Tuesday the benefits of Merck & Co.'s experimental antiviral COVID-19 pill outweigh its risks in a 13-10 vote, with several advisors saying they had concerns about use of the drug in pregnant women.</p>\n<p>The company is developing the pill, which is called molnupiravir, with privately held Ridgeback Biotherapeutics.</p>\n<p>The FDA is now expected to deliver its final decision, likely before the end of the year. The regulator often takes into account the recommendation of its advisory committees but is not required to do so.</p>\n<p>If molnupiravir is authorized by the FDA in the coming weeks, as expected, the treatment will be the first oral COVID-19 pill that patients can take at home.</p>\n<p>Members of the Antimicrobial Drugs Advisory Committee also suggested a safety-monitoring program, expressed concerns about prescribing the drug to those who are immunocompromised, and shared their concerns about the overall efficacy of the pill.</p>\n<p>\"With the continued spread of the virus and the emergence of variants, additional treatments for COVID-19 are urgently needed. That is why we are moving with speed and rigor to pursue authorizations and to accelerate broad global access to this investigational medicine,\" Dean Li, executive vice president and president of Merck Research Laboratories, said in a statement. \"We are grateful to the members of the advisory committee who reviewed our application, as well as to the patients and investigators who participated in our clinical trials, and we will continue to work with the FDA as the agency completes its review.\"</p>\n<p>Some Wall Street analysts had predicted that the advisers would vote in support of authorization, but with a cautious approach.</p>\n<p>\"Despite these reservations, molnupiravir is also likely to be approved, and demand is likely to exceed their 20 [million] course supply in 2022,\" SVB Leerink analysts wrote on Friday.</p>\n<p>Of the COVID-19 treatments that are currently available, most are used to care for very sick, hospitalized people. This includes the steroid dexamethasone and Gilead Sciences Inc.'s Veklury.</p>\n<p>The monoclonal antibodies developed by Eli Lilly & Co., Regeneron Pharmaceuticals Inc. (REGN), and Vir Biotechnology Inc. and GlaxoSmithKline can be used to treat people with mild or moderate cases of COVID-19, but these treatments have to be administered by an infusion in a clinical setting.</p>\n<p>Molnupiravir was once held as a game changer in the course of the pandemic, but its importance has shifted as new data from the clinical trial came out and a competitor stepped up.</p>\n<p>Wall Street's interest in Merck's pill began to wane in November when Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> produced even more compelling results for its COVID-19 drug candidate, demonstrating that Paxlovid reduced the risk of hospitalization and death by a stunning 89% in a clinical trial. The company filed for emergency authorization later in the month.</p>\n<p>Then, last week, Merck shared that its pill reduced the risk of hospitalization and death by 30% in a clinical trial--and not 50% as reported in the interim results. Wall Street is now factoring in growing worries about the omicron variant and the continuing need for new and better treatments for COVID-19.</p>\n<p>\"Concerns over the new omicron variant are increasing expectations on the potential of Pfizer's COVID-19 vaccine Comirnaty and updated data from Merck's oral anti-viral molnupiravir are increasing expectations for Pfizer's anti-viral Paxlovid,\" Mizuho Securities analysts told investors on Monday.</p>\n<p>Analysts were once over the moon about the sales potential of the first oral COVID-19 pill that works, predicting between $5 billion and $7 billion in sales next year alone. But the arrival of new efficacy data dragged down interest in both the drug and Merck's stock.</p>\n<p>Citi on Monday downgraded Merck's stock to neutral, from buy, citing concerns about the company's experimental HIV drug islatravir and about molnupiravir.</p>\n<p>Merck is seeking authorization for molnupiravir in adults who have tested positive for the virus, are experiencing mild or moderate symptoms, and are at high risk for severe disease. Patients are expected to start treatment within five days of symptoms.</p>\n<p>The Phase 2/3, randomized, placebo-controlled, double-blind study only enrolled people who were unvaccinated; however, it's unclear whether the pill could be used to treat vaccinated individuals with breakthrough infections if it is authorized.</p>\n<p>Molnupiravir has already been authorized for use in the U.K.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck shares jumped 5.3% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck shares jumped 5.3% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-01 17:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Merck shares jumped 5.3% in premarket trading as FDA advisers recommended its COVID-19 pill in close vote.</p>\n<p><img src=\"https://static.tigerbbs.com/52b0f147fff1ac74d32cd5d5643fe2b3\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p>\n<p>The Food and Drug Administration advisory committee said Tuesday the benefits of Merck & Co.'s experimental antiviral COVID-19 pill outweigh its risks in a 13-10 vote, with several advisors saying they had concerns about use of the drug in pregnant women.</p>\n<p>The company is developing the pill, which is called molnupiravir, with privately held Ridgeback Biotherapeutics.</p>\n<p>The FDA is now expected to deliver its final decision, likely before the end of the year. The regulator often takes into account the recommendation of its advisory committees but is not required to do so.</p>\n<p>If molnupiravir is authorized by the FDA in the coming weeks, as expected, the treatment will be the first oral COVID-19 pill that patients can take at home.</p>\n<p>Members of the Antimicrobial Drugs Advisory Committee also suggested a safety-monitoring program, expressed concerns about prescribing the drug to those who are immunocompromised, and shared their concerns about the overall efficacy of the pill.</p>\n<p>\"With the continued spread of the virus and the emergence of variants, additional treatments for COVID-19 are urgently needed. That is why we are moving with speed and rigor to pursue authorizations and to accelerate broad global access to this investigational medicine,\" Dean Li, executive vice president and president of Merck Research Laboratories, said in a statement. \"We are grateful to the members of the advisory committee who reviewed our application, as well as to the patients and investigators who participated in our clinical trials, and we will continue to work with the FDA as the agency completes its review.\"</p>\n<p>Some Wall Street analysts had predicted that the advisers would vote in support of authorization, but with a cautious approach.</p>\n<p>\"Despite these reservations, molnupiravir is also likely to be approved, and demand is likely to exceed their 20 [million] course supply in 2022,\" SVB Leerink analysts wrote on Friday.</p>\n<p>Of the COVID-19 treatments that are currently available, most are used to care for very sick, hospitalized people. This includes the steroid dexamethasone and Gilead Sciences Inc.'s Veklury.</p>\n<p>The monoclonal antibodies developed by Eli Lilly & Co., Regeneron Pharmaceuticals Inc. (REGN), and Vir Biotechnology Inc. and GlaxoSmithKline can be used to treat people with mild or moderate cases of COVID-19, but these treatments have to be administered by an infusion in a clinical setting.</p>\n<p>Molnupiravir was once held as a game changer in the course of the pandemic, but its importance has shifted as new data from the clinical trial came out and a competitor stepped up.</p>\n<p>Wall Street's interest in Merck's pill began to wane in November when Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> produced even more compelling results for its COVID-19 drug candidate, demonstrating that Paxlovid reduced the risk of hospitalization and death by a stunning 89% in a clinical trial. The company filed for emergency authorization later in the month.</p>\n<p>Then, last week, Merck shared that its pill reduced the risk of hospitalization and death by 30% in a clinical trial--and not 50% as reported in the interim results. Wall Street is now factoring in growing worries about the omicron variant and the continuing need for new and better treatments for COVID-19.</p>\n<p>\"Concerns over the new omicron variant are increasing expectations on the potential of Pfizer's COVID-19 vaccine Comirnaty and updated data from Merck's oral anti-viral molnupiravir are increasing expectations for Pfizer's anti-viral Paxlovid,\" Mizuho Securities analysts told investors on Monday.</p>\n<p>Analysts were once over the moon about the sales potential of the first oral COVID-19 pill that works, predicting between $5 billion and $7 billion in sales next year alone. But the arrival of new efficacy data dragged down interest in both the drug and Merck's stock.</p>\n<p>Citi on Monday downgraded Merck's stock to neutral, from buy, citing concerns about the company's experimental HIV drug islatravir and about molnupiravir.</p>\n<p>Merck is seeking authorization for molnupiravir in adults who have tested positive for the virus, are experiencing mild or moderate symptoms, and are at high risk for severe disease. Patients are expected to start treatment within five days of symptoms.</p>\n<p>The Phase 2/3, randomized, placebo-controlled, double-blind study only enrolled people who were unvaccinated; however, it's unclear whether the pill could be used to treat vaccinated individuals with breakthrough infections if it is authorized.</p>\n<p>Molnupiravir has already been authorized for use in the U.K.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116877933","content_text":"Merck shares jumped 5.3% in premarket trading as FDA advisers recommended its COVID-19 pill in close vote.\n\nThe Food and Drug Administration advisory committee said Tuesday the benefits of Merck & Co.'s experimental antiviral COVID-19 pill outweigh its risks in a 13-10 vote, with several advisors saying they had concerns about use of the drug in pregnant women.\nThe company is developing the pill, which is called molnupiravir, with privately held Ridgeback Biotherapeutics.\nThe FDA is now expected to deliver its final decision, likely before the end of the year. The regulator often takes into account the recommendation of its advisory committees but is not required to do so.\nIf molnupiravir is authorized by the FDA in the coming weeks, as expected, the treatment will be the first oral COVID-19 pill that patients can take at home.\nMembers of the Antimicrobial Drugs Advisory Committee also suggested a safety-monitoring program, expressed concerns about prescribing the drug to those who are immunocompromised, and shared their concerns about the overall efficacy of the pill.\n\"With the continued spread of the virus and the emergence of variants, additional treatments for COVID-19 are urgently needed. That is why we are moving with speed and rigor to pursue authorizations and to accelerate broad global access to this investigational medicine,\" Dean Li, executive vice president and president of Merck Research Laboratories, said in a statement. \"We are grateful to the members of the advisory committee who reviewed our application, as well as to the patients and investigators who participated in our clinical trials, and we will continue to work with the FDA as the agency completes its review.\"\nSome Wall Street analysts had predicted that the advisers would vote in support of authorization, but with a cautious approach.\n\"Despite these reservations, molnupiravir is also likely to be approved, and demand is likely to exceed their 20 [million] course supply in 2022,\" SVB Leerink analysts wrote on Friday.\nOf the COVID-19 treatments that are currently available, most are used to care for very sick, hospitalized people. This includes the steroid dexamethasone and Gilead Sciences Inc.'s Veklury.\nThe monoclonal antibodies developed by Eli Lilly & Co., Regeneron Pharmaceuticals Inc. (REGN), and Vir Biotechnology Inc. and GlaxoSmithKline can be used to treat people with mild or moderate cases of COVID-19, but these treatments have to be administered by an infusion in a clinical setting.\nMolnupiravir was once held as a game changer in the course of the pandemic, but its importance has shifted as new data from the clinical trial came out and a competitor stepped up.\nWall Street's interest in Merck's pill began to wane in November when Pfizer Inc. $(PFE)$ produced even more compelling results for its COVID-19 drug candidate, demonstrating that Paxlovid reduced the risk of hospitalization and death by a stunning 89% in a clinical trial. The company filed for emergency authorization later in the month.\nThen, last week, Merck shared that its pill reduced the risk of hospitalization and death by 30% in a clinical trial--and not 50% as reported in the interim results. Wall Street is now factoring in growing worries about the omicron variant and the continuing need for new and better treatments for COVID-19.\n\"Concerns over the new omicron variant are increasing expectations on the potential of Pfizer's COVID-19 vaccine Comirnaty and updated data from Merck's oral anti-viral molnupiravir are increasing expectations for Pfizer's anti-viral Paxlovid,\" Mizuho Securities analysts told investors on Monday.\nAnalysts were once over the moon about the sales potential of the first oral COVID-19 pill that works, predicting between $5 billion and $7 billion in sales next year alone. But the arrival of new efficacy data dragged down interest in both the drug and Merck's stock.\nCiti on Monday downgraded Merck's stock to neutral, from buy, citing concerns about the company's experimental HIV drug islatravir and about molnupiravir.\nMerck is seeking authorization for molnupiravir in adults who have tested positive for the virus, are experiencing mild or moderate symptoms, and are at high risk for severe disease. Patients are expected to start treatment within five days of symptoms.\nThe Phase 2/3, randomized, placebo-controlled, double-blind study only enrolled people who were unvaccinated; however, it's unclear whether the pill could be used to treat vaccinated individuals with breakthrough infections if it is authorized.\nMolnupiravir has already been authorized for use in the U.K.","news_type":1},"isVote":1,"tweetType":1,"viewCount":575,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879574401,"gmtCreate":1636758992535,"gmtModify":1636758992535,"author":{"id":"3582016082149562","authorId":"3582016082149562","name":"Charis4455","avatar":"https://static.tigerbbs.com/170154e3e4358555276582209b5e7550","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582016082149562","authorIdStr":"3582016082149562"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879574401","repostId":"1163118124","repostType":4,"isVote":1,"tweetType":1,"viewCount":795,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607649897,"gmtCreate":1639536362062,"gmtModify":1639536362062,"author":{"id":"3582016082149562","authorId":"3582016082149562","name":"Charis4455","avatar":"https://static.tigerbbs.com/170154e3e4358555276582209b5e7550","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582016082149562","authorIdStr":"3582016082149562"},"themes":[],"htmlText":":(","listText":":(","text":":(","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607649897","repostId":"1180160205","repostType":4,"repost":{"id":"1180160205","kind":"news","pubTimestamp":1639534172,"share":"https://www.laohu8.com/m/news/1180160205?lang=&edition=full","pubTime":"2021-12-15 10:09","market":"us","language":"en","title":"Upstart Shares Have Plunged, But Stay Away for Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1180160205","media":"InvestorPlace","summary":"Even after crashing, UPST stock remains risky","content":"<p><b>Upstart</b> (NASDAQ:<b><u>UPST</u></b>) has been one of this year’s top performers. Shares of UPST stock are up over 250% year-to-date (YTD), from around $40 at the start of 2021 to $145 as of the close of Dec. 14.</p>\n<p>You probably wouldn’t realize that if you’ve just tuned into the Upstart story, however. While UPST is up huge on the year, the gains have shrunk dramatically from where they were back in October. At that point, the stock had briefly hit $400 as speculative fervor peaked.</p>\n<p>The top soon came following an embarrassing interview on<i>CNBC</i>. The business channel had on stock trader Mark Minervini to discuss UPST stock and Minervini talked up the company’s strong technicals and momentum. However, when the <i>CNBC</i> host asked Minervini to explain Upstart’s business model, he froze up. Seemingly unable to answer, Minervini blamed audio issues and the interview abruptly ended.</p>\n<p>That moment went viral and the UPST stock price soon started to crash. It seems a lot of people, like Minervini, appreciated Upstart primarily because of its strong price performance rather than the company’s actual business. With the momentum in the stock long gone, however, is it time to buy in during this correction?</p>\n<p><b>UPST Stock: Rapid But Slowing Growth</b></p>\n<p>At first glance, Upstart’s third-quarter earnings report didn’t look too bad. The company beat estimates on both the top and bottom line. In particular, the earnings figure was substantially ahead of expectations. Based on that, you might have thought Upstart would rally on the results, or at least hold its ground. Instead, UPST stock immediately plunged 20% upon the Q3 release.</p>\n<p>What went wrong? For one thing, investors had their expectations in the stratosphere. Analysts may have had more conservative numbers, but quick money traders were expecting massive growth in Q3 after Q2’s blowout earnings. Instead, Q3 was only moderately ahead of expectations.</p>\n<p>Specifically, Upstart’s growth rate showed the issues. For the quarter, revenue growth slowed to 18% sequentially versus 60% in Q2. That’s a massive decline. And that came even as some analysts have become concerned that Upstart may be lowering loan quality standards to attract more business. Adding to that point, while the company grew revenues sequentially, the contribution margin actually declined slightly in Q3 versus Q2.</p>\n<p>Long story short, Upstart’s incredible growth phase appears to be drawing to a close. Meanwhile, shares are trading at 100 times this year’s earnings and a projected 77 times forward earnings, according to<i>Seeking Alpha</i>. That’s far too high for a company with rapidly slowing revenue and earnings growth. On top of that, add the fact that it faces substantial cyclical concerns if and when the economy turns downward once again.</p>\n<p>UPST stock completed its initial public offering (IPO) at $20 per share just a year ago. It’s no surprise that the stock is having trouble supporting a price 10 times that high just a year later. Momentum traders got way over their skis on this one.</p>\n<p><b>Analysts Also Worry About Valuation</b></p>\n<p>I’m hardly the only person that’s concerned about Upstart’s valuation, too. For example, Morgan Stanley initiated coverage of Upstart shares last week with a neutral rating.</p>\n<p>Morgan Stanley’s James Faucette did credit the company for its rapid growth. However, Faucette also warned that it has benefitted from unusually favorable credit conditions among other tailwinds. The analyst is monitoring Upstart for incremental changes to the growth story.</p>\n<p>In the meantime, it’s not exactly encouraging that Faucette assigned UPST stock a neutral rating on shares with the stock already back under $200. Just because this name hit $400 before doesn’t necessarily mean it’s a bargain below $200 per share.</p>\n<p><b>The Verdict on Upstart</b></p>\n<p>The last time I covered Upstart, I took an unequivocally negative view, warning that it was “overvalued and set to crash.”Indeed, the stock has plunged from $300 to below $160 since that article’s publication. That wasn’t too complicated of a call — there was absolutely no way to justify a valuation anywhere near that level.</p>\n<p>However, the investment case now is a little more nuanced with the stock down a quick 50%. At this point, shares are oversold — rather than overbought — on a short-term basis. To some extent, UPST stock has gotten hit with tax loss and momentum-based selling as people that bought at $300 and above sell out of shares to move their capital elsewhere.</p>\n<p>So, would it be surprising if UPST stock bounces once the calendar flips into 2022? Not at all. Over the longer-term, though, Upstart remains seriously overvalued compared to its medium-term business prospects. The company will need to expand into more lending verticals — without letting credit quality slide — if it’s going to support a triple-digit price going forward.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Upstart Shares Have Plunged, But Stay Away for Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUpstart Shares Have Plunged, But Stay Away for Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-15 10:09 GMT+8 <a href=https://investorplace.com/2021/12/upst-stock-has-plunged-but-stay-away-from-shares-for-now/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Upstart (NASDAQ:UPST) has been one of this year’s top performers. Shares of UPST stock are up over 250% year-to-date (YTD), from around $40 at the start of 2021 to $145 as of the close of Dec. 14.\nYou...</p>\n\n<a href=\"https://investorplace.com/2021/12/upst-stock-has-plunged-but-stay-away-from-shares-for-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UPST":"Upstart Holdings, Inc."},"source_url":"https://investorplace.com/2021/12/upst-stock-has-plunged-but-stay-away-from-shares-for-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180160205","content_text":"Upstart (NASDAQ:UPST) has been one of this year’s top performers. Shares of UPST stock are up over 250% year-to-date (YTD), from around $40 at the start of 2021 to $145 as of the close of Dec. 14.\nYou probably wouldn’t realize that if you’ve just tuned into the Upstart story, however. While UPST is up huge on the year, the gains have shrunk dramatically from where they were back in October. At that point, the stock had briefly hit $400 as speculative fervor peaked.\nThe top soon came following an embarrassing interview onCNBC. The business channel had on stock trader Mark Minervini to discuss UPST stock and Minervini talked up the company’s strong technicals and momentum. However, when the CNBC host asked Minervini to explain Upstart’s business model, he froze up. Seemingly unable to answer, Minervini blamed audio issues and the interview abruptly ended.\nThat moment went viral and the UPST stock price soon started to crash. It seems a lot of people, like Minervini, appreciated Upstart primarily because of its strong price performance rather than the company’s actual business. With the momentum in the stock long gone, however, is it time to buy in during this correction?\nUPST Stock: Rapid But Slowing Growth\nAt first glance, Upstart’s third-quarter earnings report didn’t look too bad. The company beat estimates on both the top and bottom line. In particular, the earnings figure was substantially ahead of expectations. Based on that, you might have thought Upstart would rally on the results, or at least hold its ground. Instead, UPST stock immediately plunged 20% upon the Q3 release.\nWhat went wrong? For one thing, investors had their expectations in the stratosphere. Analysts may have had more conservative numbers, but quick money traders were expecting massive growth in Q3 after Q2’s blowout earnings. Instead, Q3 was only moderately ahead of expectations.\nSpecifically, Upstart’s growth rate showed the issues. For the quarter, revenue growth slowed to 18% sequentially versus 60% in Q2. That’s a massive decline. And that came even as some analysts have become concerned that Upstart may be lowering loan quality standards to attract more business. Adding to that point, while the company grew revenues sequentially, the contribution margin actually declined slightly in Q3 versus Q2.\nLong story short, Upstart’s incredible growth phase appears to be drawing to a close. Meanwhile, shares are trading at 100 times this year’s earnings and a projected 77 times forward earnings, according toSeeking Alpha. That’s far too high for a company with rapidly slowing revenue and earnings growth. On top of that, add the fact that it faces substantial cyclical concerns if and when the economy turns downward once again.\nUPST stock completed its initial public offering (IPO) at $20 per share just a year ago. It’s no surprise that the stock is having trouble supporting a price 10 times that high just a year later. Momentum traders got way over their skis on this one.\nAnalysts Also Worry About Valuation\nI’m hardly the only person that’s concerned about Upstart’s valuation, too. For example, Morgan Stanley initiated coverage of Upstart shares last week with a neutral rating.\nMorgan Stanley’s James Faucette did credit the company for its rapid growth. However, Faucette also warned that it has benefitted from unusually favorable credit conditions among other tailwinds. The analyst is monitoring Upstart for incremental changes to the growth story.\nIn the meantime, it’s not exactly encouraging that Faucette assigned UPST stock a neutral rating on shares with the stock already back under $200. Just because this name hit $400 before doesn’t necessarily mean it’s a bargain below $200 per share.\nThe Verdict on Upstart\nThe last time I covered Upstart, I took an unequivocally negative view, warning that it was “overvalued and set to crash.”Indeed, the stock has plunged from $300 to below $160 since that article’s publication. That wasn’t too complicated of a call — there was absolutely no way to justify a valuation anywhere near that level.\nHowever, the investment case now is a little more nuanced with the stock down a quick 50%. At this point, shares are oversold — rather than overbought — on a short-term basis. To some extent, UPST stock has gotten hit with tax loss and momentum-based selling as people that bought at $300 and above sell out of shares to move their capital elsewhere.\nSo, would it be surprising if UPST stock bounces once the calendar flips into 2022? Not at all. Over the longer-term, though, Upstart remains seriously overvalued compared to its medium-term business prospects. The company will need to expand into more lending verticals — without letting credit quality slide — if it’s going to support a triple-digit price going forward.","news_type":1},"isVote":1,"tweetType":1,"viewCount":688,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
